The ALS Association Golden West Chapter has honored Mitsubishi Tanabe Pharma America (MTPA) with its Essey Commitment to Cures award for advancing research and trials into treatments for amyotrophic lateral sclerosis (ALS) and other efforts. The presentation took place Nov. 15 in San Francisco at the 2019 Champions…
News
Amyotrophic lateral sclerosis (ALS) is highly prevalent among young U.S. war veterans deployed post-9/11, particularly Air Force personnel, tactical operation officers, and health care workers, a recent study suggests. The findings suggest that there is an early onset of ALS among deployed military service members, the researchers said. Titled…
Aquestive Therapeutics has granted a development and commercialization license to Zambon Pharma for its investigational oral film formulation of riluzole as a treatment for amyotrophic lateral sclerosis (ALS) in the European Union (EU). Under the terms of the agreement, Zambon will be…
Small molecule inhibitors that block the activity of SARM1 — an enzyme that plays a key role in nerve cell degeneration — prevent the degeneration of axons in mice and cellular models of disease, a preclinical study has found. These findings may be the first steps towards the development…
Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…
News
MRI-guided Focused Ultrasounds Can Safely Open Brain-Blood Barrier in ALS Patients, Trial Shows
The non-invasive delivery of ultrasound waves in a controlled, targeted manner can be safely used to open the blood-brain barrier in people with amyotrophic lateral sclerosis (ALS), giving temporary access to their motor cortex, results from a first-in-human trial show. The approach — called magnetic resonance guided…
News
Aural, TGen Collaborate on Trial Assessing Effects of Acupuncture on Recently Diagnosed ALS Patients
Aural Analytics and the Translational Genomics Research Institute (TGen) will collaborate on a new acupuncture clinical trial to assess how the treatment affects speech in people recently diagnosed with amyotrophic lateral sclerosis (ALS). TGen, a nonprofit medical research institute, will sponsor…
Radicava (edaravone), an intravenous treatment for amyotrophic lateral sclerosis (ALS), is now commercially available in Canada, Mitsubishi Tanabe Pharma Canada (MTP-CA) has announced. The treatment was approved in Canada in October 2018, and has since been under the regulatory process that determines how, where, and at what…
News
With $300K Grant, ALS Never Surrender Foundation Launches Mobile App to Track Disease Progression
The ALS Association has awarded the nonprofit ALS Never Surrender Foundation a $300,000 grant to bring its precision point mobile technology app to patient progression research trials nationwide. Called ALS iNVOLVE/eNGAGE, the application enables the remote tracking of vitals including muscle control, dexterity, speech, breathing and…
News
Exercise Helps to Slow Motor Neuron Loss in ALS, Study Suggests, But Type of Activity May Be Key
Exercise appears to benefit people with amyotrophic lateral sclerosis (ALS) by normalizing molecular changes that occur at the junction of nerves and muscles, but by degrees that depend on the type of exercise, a study in a mouse model of ALS suggests. While running and swimming both lessened the profound molecular…
Recent Posts
- Trial, error, and toe covers: Learning to adapt in life with ALS
- 5-year survival seen for over 40% of ALS patients on masitinib in trial
- Long-term air pollution exposure shows no clear link to ALS in UK study
- Masitinib trial insurance offers a safety net for ALS research
- Spontaneous mutations may underlie some sporadic ALS cases